Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 2Thoracic 1Gastrointestinal 1Breast 1

Conditions

Small Cell Lung Carcinoma 1Lung Neoplasms 1Drug-Related Side Effects and Adverse Reactions 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Carboplatin 1174Cisplatin 891Pemetrexed 847pembrolizumab 626Paclitaxel 609Docetaxel 539Gemcitabine 428Radiotherapy 393Erlotinib Hydrochloride 381Nivolumab 344Bevacizumab 337Etoposide 297durvalumab 264Drug Therapy 260osimertinib 237atezolizumab 225Radiosurgery 196Gefitinib 186Vinorelbine 149Magnetic Resonance Spectroscopy 132Ipilimumab 129130-nm albumin-bound paclitaxel 125Cetuximab 113Blood Specimen Collection 106anlotinib 105tislelizumab 103Topotecan 103Specimen Handling 102Surgical Procedures, Operative 101Cyclophosphamide 101

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Tocopherols × Thoracic × Clear all
NCT00002586 2020-05-15

13-Cis

University of Colorado, Denver

Phase 2 Completed
96 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Small Cell Lung Carcinoma, Drug-Related Side Effects and Adverse Reactions

Data powered by HemOnc (CC BY 4.0) Colophon âš¡